Want to track TLX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
TLX is not paying dividends to its shareholders.
The last earnings report, released on Feb 18, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.0003%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on ASX (AUD).
Telix Pharmaceuticals Limited (TLX) FAQ
On which exchange is it traded?
Telix Pharmaceuticals Limited is listed on ASX.
What is its stock symbol?
The ticker symbol is TLX.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Telix Pharmaceuticals Limited ever had a stock split?
No, there has never been a stock split.
Telix Pharmaceuticals Limited Profile
| Biotechnology Industry | Healthcare Sector | Christian Behrenbruch CEO | ASX Exchange | AU000000TLX2 ISIN |
| AU Country | 415 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company, established in 2015, with its headquarters in North Melbourne, Australia. The company operates globally, focusing its efforts on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals as well as related medical devices aimed at treating cancer and rare diseases. Its operational footprint spans across various countries including Australia, Belgium, Japan, Switzerland, and the United States. Telix Pharmaceuticals is at the forefront of advancing radiopharmaceuticals for cancer diagnosis and treatment, leveraging cutting-edge scientific research to meet the critical needs of patients worldwide.
Products and Services
- **TLX591-CDx**: For the diagnosis and treatment of metastatic castrate-resistant prostate cancer. This product represents a targeted approach to identify and manage one of the most challenging stages of prostate cancer. - **TLX250-CDx**: Currently in Phase III clinical trials, this product is aimed at the treatment and diagnosis of renal (kidney) cancer. It demonstrates the company's commitment to addressing cancers with significant unmet needs. - **TLX101-CDx**: Dedicated to the diagnosis and treatment of glioblastoma (brain cancer), this radiopharmaceutical is under Phase II clinical development. Glioblastoma is known for its aggressiveness and poor prognosis, highlighting the importance of such research. - **TLX66-CDx**: Aims at bone marrow conditioning and treating rare diseases, showing the company's versatility in targeting different therapeutic areas beyond solid tumors. - **TLX300-CDx**: In Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma, emphasizing Telix Pharmaceuticals' efforts in rare cancer types. - **TLX250**: This Phase II clinical trial product focuses on the diagnosis and treatment of kidney cancer, supporting the earlier-mentioned TLX250-CDx with its aligned objectives. - **TLX591**: Another key player in the company's portfolio, this Phase III clinical trial product is for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, along with TLX591-CDx, underscoring a strong focus in this disease area. - **TLX101**: Under Phase II clinical trials for glioblastoma (brain cancer) treatment, this product parallels the efforts of TLX101-CDx in attacking one of the most devastating forms of cancer. - **TLX66**: Focused on bone marrow conditioning and rare diseases, this Phase II clinical trial product represents the company's commitment to broadening its impact across various patient populations. - **TLX300**: A Phase I clinical trial product for the diagnosis and treatment of soft tissue sarcoma, TLX300 continues the company's pursuit of solutions for less common but equally challenging cancer types. - **TLX592**: A development candidate specifically designated for prostate cancer therapy through targeted alpha therapy, showcasing Telix's exploration into more advanced treatment methodologies. - **TLX599-CDx**: Focused on demonstrating efficacy as a prostate cancer imaging agent, TLX599-CDx embodies the company's continuous innovation in the diagnosis and management of prostate cancer.Contact Information
Address: 55 Flemington Road
Phone: 61 3 3093 3897
Website: https://telixpharma.com
